Intracellular mechanism(s) that contribute to promiscuous signaling via oncogenic KIT in systemic mastocytosis (SM) and acute myelogenous leukemia (AML) are poorly understood.
Introduction
Gain-of-function mutations in KIT receptor in humans are associated with gastrointestinal stromal tumors (GIST), systemic mastocytosis (SM), and acute myelogenous leukemia (AML) [1] [2] [3] [4] .
An activating KIT receptor mutation of aspartic acid to valine at codon 814 in mice (KITD814V) or codon 816 in humans (KITD816V) results in altered substrate recognition and constitutive tyrosine autophosphorylation leading to promiscuous signaling 5, 6 . Consequently, cell lines and primary bone marrow (BM) cells that express the oncogenic KITD814V demonstrate ligand independent proliferation in vitro and MPD in vivo [5] [6] [7] [8] [9] . However, the intracellular signals that contribute to KITD814V induced MPD are not known. Although activating mutations of KIT involving the juxtamembrane domain found in GIST are highly sensitive to inhibition by imatinib mesylate (i.e. Gleevec), KIT mutations within tyrosine kinase domain found in SM and AML, including KITD816V, are relatively resistant to imatinib treatment [10] [11] [12] . Thus, it is vital to identify novel drug targets for diseases involving KITD816V mutation.
Emerging data suggests an essential role for SHP2 in MPD. SHP2 is a protein tyrosine phosphatase that is encoded by PTPN11 gene and has been implicated in diverse signaling pathways induced by a number of stimuli including growth factors, cytokines, extracellular matrix, and even cellular stress [13] [14] [15] . Given that activating mutations in SHP2 have been found in leukemias and solid tumors 16, 17 , efforts are ongoing to define the potential efficacy of SHP2 phosphatase inhibition in diseases bearing SHP2 hyperactivation, either due to activating SHP2 mutations or those in which SHP2 collaborates with other oncogenes. Utilizing genetic approaches, including primary bone marrow (BM) cells derived from SHP2-/-and Gab2-/-mice and a novel SHP2 inhibitor, II-B08, identified from a focused library of indole-based salicylic acid derivatives 18 , we demonstrate that SHP2 is essential for KITD814V induced MPD. We further demonstrate that SHP2 constitutively binds to p85α and Gab2 in KITD814V bearing cells, which
For personal use only. on April 13, 2017. by guest www.bloodjournal.org From 4 can be disrupted by II-B08 resulting in impaired ligand independent growth in vitro and MPD in vivo. Importantly, tyrosine residue at 719 within the intracellular KIT domain plays a unique role in regulating KITD814V induced proliferation and survival in vitro, and MPD in vivo through recruitment of p85α, SHP2 and Gab2 protein complex to KITD814V and activation of PI3Kinase.
Consistently, the SHP2 inhibitor, II-B08, enhances the efficacy of PI3Kinase inhibitor in treating KITD814V induced MPD in vivo. We define SHP2 as a novel therapeutic target for hematologic malignancies involving oncogenic KIT and suggest that treating KITD814V bearing cells with a combination of a tyrosine phosphatase and a lipid kinase inhibitor may be a prudent and novel approach for treating diseases involving oncogenic forms of KIT.
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Materials and Methods

SHP2 Inhibitor II-B08
The discovery and characterization of SHP2 inhibitor II-B08 has been described previously 18 .
Antibodies and Cytokines
Antibodies and cytokines used in this study are described in Supplemental Methods.
Mice
C57BL/6 and C3H/HeJ mice were purchased from Jackson Laboratory (Bar Harbor, ME). Mice Gab2-/-mice and mast cell deficient Kit W-sh/W-sh mice were previously described 22, 23 . All mice used in this study were between 6 to 12 weeks of age. These mice were maintained under specific pathogen-free conditions at the Indiana University Laboratory Animal Research Center (Indianapolis, IN), and the study was approved by the Institutional Animal Care and Use
Committee of the Indiana University School of Medicine.
Construction of wild-type (WT) and mutant KIT receptors
The WT KIT and KITD814V were inserted into the bicistronic retroviral vector, MIEG3, upstream of the internal ribosome entry site (IRES) and the enhanced green fluorescent protein (EGFP) gene as previously described 8 . Chimeric KIT receptors were generated as previously
For personal use only. on April 13, 2017. by guest www.bloodjournal.org From 6 described 24 . Utilizing these chimeric KIT receptors as template, we generated the mutant KITD814V and KITD814V with none (KITD814V-F7) or single intracellular tyrosine add-back mutant at codon 719 (KITD814V-Y719) using the Quick change Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA) and the following primer pair (forward: 5'-GGG CTA GCC AGA GTC ATC AGG AAT GAT TCG-3'; reverse: 5'-CGA ATC ATT CCT GAT GAC TCT GGC TAG CCC-3'). All these mutated KITD814V receptors were verified by direct sequencing.
Expression of WT and mutant KIT receptors in 32D cells and primary HSC/Ps
32D cells and primary LDMNC were transduced with WT or chimeric KIT receptors as described previously and in detail in supplemental methods 8, 25 .
Murine bone marrow transplantation 1 x 10 6 transduced cells and 1 x 10 5 supporting fresh splenocytes from C57BL/6 mice were intravenously injected through tail vein into lethally irradiated (1100 cGY-split dose) recipient mice as described previously 8, 25 .
Proliferation
Proliferation was assessed by conducting a thymidine incorporation assay as previously described 8, 25 .
Apoptosis
Cells were subjected to apoptosis assay with Annexin V: PE Apoptosis Detection Kit I (BD Biosciences Pharmingen, San Diego, CA) according to the manufacturer's protocol as described previously 25 .
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Immunoprecipitation and western bloting
Immunoprecipitation (IP) and western blot analysis were performed as previously reported 24 .
Pharmacokinetic studies
For pharmacokinetic studies, II-B08 levels were quantified in the mouse serum by liquid-liquid extraction and HPLC-MS/MS (API 4000) using compound II-B05 18 (inactive II-B08 analogue) as the internal standard. The Q1/Q3's for II-B08 and II-B05 were 557/304 and 480/304, respectively, with a lower limit of quantification for the assay of 3 ng/mL using 20 mL of serum. Assay development and execution was performed by Dr. David Jones (Indiana University Clinical Pharmacology Analytical Core [CPAC] ). Mice received 100 mg/kg II-B08
intraperitoneally each day X 7 days followed by collection of blood at 30 min, 1 hour, 4 hours, and 24 hours after the first injection. A serum sample was also collected 24 hours after the final (7 th ) injection (168 hours after the first injection). We determined a C max of 155 μM +/-24.7. Twenty-four hours after 1 st dose, a trough concentration of 0.14 μM +/-0.002 was found (Supplemental Figure 1) , which is about 100-fold lower than effective concentrations of II-B08 in vitro (~10 μM). However, after a cumulative dose of 700 mg/kg (7 doses of 100 mg/kg over 7 days), we found a steady state concentration of 6.4 μM +/-6.3 (Supplemental Figure 1) . 
In vivo treatment of leukemic mice
Results
Constitutive activation of SHP2 in cells bearing KITD814V
To determine the role of SHP2 in KITD814V induced myeloproliferative disease (MPD), we examined if SHP2 is hyperactivated in cells bearing KITD814V and if SHP2 phosphatase inhibition using a novel SHP2 inhibitor, II-B08, normalizes SHP2 hyperactivation 18 . We have recently described the generation and synthesis of II-B08 18 . As seen in Figure 1A 
Constitutive phosphorylation of SHP2 is associated with ligand independent growth and survival of KITD814V bearing cells
Since constitutive phosphorylation of SHP2 was observed in cells bearing KITD814V, we tested whether inhibition of constitutive SHP2 phosphorylation using II-B08 would suppress KITD814V
induced ligand independent growth in vitro. As seen in Figure 1B , II-B08 treatment resulted in only modest repression in the growth of cells bearing WT KIT. In contrast, a significant dose dependent repression in ligand independent growth of 32D cells bearing KITD814V was observed in the presence of II-B08 ( Figure 1B ). Similar results were obtained using primary hematopoietic stem and progenitor (HSC/P) cells bearing WT KIT or KITD814V in the presence of II-B08 ( Figure 1C ).
SHP2 is functionally essential for KITD814V induced ligand independent growth
We further examined the functional contribution of SHP2 in KITD814V induced ligand independent growth. Since SHP2 deficiency in mice results in embryonic lethality, we therefore showed ligand independent growth, but not WT KIT bearing cells ( Figure 1D ). Deficiency of SHP2 resulted in significant repression (~75%) in ligand independent growth of cells bearing KITD814V. It is important to point out that loss of SHP2 also impairs the proliferation of WT KIT expressing BM cells in response to SCF stimulation; however, the reduction in proliferation under these conditions is modest relative to the inhibition observed in SHP2 deficient BM cells bearing KITD814V receptor (Supplemental Figure 2D ). In addition, partial loss of SHP2 protein in the context of KITD814V only results in 30% growth inhibition indicating that the amount of SHP2 protein status to a large extent determines functional outcomes in normal vs. KITD814V
bearing cells (Supplemental Figure 2E) . Furthermore, chemical epistasis experiments utilizing SHP2-/-BM cells expressing WT KIT or KITD814V did not show a further reduction in ligand independent growth in the presence of II-B08, suggesting that II-B08 is highly specific for SHP2 under test conditions ( Figure 1E and Supplemental Figure 3 ). However, we cannot completely rule out the possibility of off-target effects of II-B08 at this point. (Figure 2A ). To further confirm the role of SHP2 in activating KIT induced MPD, we isolated CD34+ cells from human cord blood cells, transduced them with a retrovirus expressing KITD816V and analyzed constitutive growth in the presence of increasing doses of II-B08. As seen in Figure 2B , II-B08 treatment resulted in a dose dependent repression in constitutive growth of primary human CD34+ cells bearing KITD816V.
SHP2 inhibitor, II-B08, prolongs the survival of mice transplanted with cells bearing KITD814V
To further determine the in vivo anti-leukemic effect of II-B08, syngeneic C3H/HeJ mice transplanted with myeloid cells bearing oncogenic KITD814V were treated with either DMSO or II-B08 (100 mg/kg body weight per day) for 14 days. In normal control mice, this dose of II-B08
was well tolerated and no drug related tissue toxicity was observed (Supplemental Figure 1, 4 and 5). The drug dose employed in these studies resulted in 50% inhibition of SHP2 phosphorylation in splenocytes ( Figure 3A ). As seen in Figure 3B , mice treated with II-B08 survived significantly longer compared to vehicle (DMSO) treated group (*p<0.05). In addition, spleen and liver weight of II-B08 treated mice was significantly reduced compared to DMSO treated group ( Figure 3C and 3D).
To determine the in vivo specificity of II-B08 for SHP2, we treated WT and SHP2-/-mice with II-B08 for 7 days and analyzed blood parameters. Consistent with previously published data 20 , SHP2-/-mice show significantly reduced WBC counts, bone marrow (BM) cellularity and splenic cellularity (Supplemental Figure 6 ). We did not see any significant differences in WBC counts, BM cellularity and splenic cellularity between SHP2-/-mice treated with vehicle (DMSO) or II-B08, suggesting that II-B08 is specific for SHP2 (Supplemental Figure 6 ).
SHP2 is required for ligand independent survival of KITD814V bearing cells
To determine the mechanism behind the repression in ligand independent growth of cells bearing KITD814V by II-B08, we examined the role of SHP2 in cell survival and cycling. II-B08 treatment resulted in a significant dose dependent increase in apoptosis of cells bearing KITD814V compared to WT KIT bearing cells ( Figure 4A ). To further confirm the role of SHP2 in KITD814V induced cell survival and to establish IIB08 specificity for SHP2, primary HSC/Ps from WT or SHP2-/-mice were transduced with WT KIT or KITD814V and examined for apoptosis. As seen in Figure 4B , WT cells bearing KITD814V showed increased survival in the absence of growth factors compared to WT KIT expressing cells. In contrast, deficiency of SHP2 resulted in a significant reduction in survival of cells bearing KITD814V. In addition, no significant difference in cycling of cells bearing WT KIT or KITD814V was observed in the presence of II-B08 (Supplemental Figure 7) . These results suggest that the reduced growth of cells bearing KITD814V in the presence of II-B08 is mainly due to cell survival, but not cycling.
Constitutive phosphorylation of SHP2 is associated with binding of SHP2 with PI3Kinase regulatory subunit p85α and/or Gab2 in oncogenic KITD814V bearing cells
To further determine the signaling molecules that co-operate with SHP2 in KITD814V induced MPD, we examined proteins that potentially interact with SHP2 in KITD814V bearing cells and whether inhibition of SHP2 phosphorylation by II-B08 suppresses these co-operating protein interactions. Given that SHP2 and Gab2 have been shown to interact with p85α
27,28 , we tested 1 3 whether SHP2, Gab2 and p85α form a constitutive protein complex in KITD814V bearing cells.
As seen in Figure 5A , SHP2 constitutively bound to p85α and Gab2 in cells bearing KITD814V, but not in WT KIT expressing cells. Treatment of these cells with II-B08 significantly inhibited the formation of this complex ( Figure 5A ). Similar results were observed in cells derived from mastocytosis patient (HMC1.2 cells) bearing the activating KIT mutation (Supplemental Figure   8 ). These results suggest that phosphorylation of SHP2 is associated with formation of a protein complex involving p85α, SHP2 and/or Gab2 in KITD814V bearing cells.
Involvement of Gab2 in oncogenic KITD814V induced ligand independent growth
Since recent studies have also shown that Gab2 is an essential mediator for the pathogenic effects of Ptpn11 mutations, we examined the contribution of Gab2 in KITD814V induced ligand independent growth 29 . We transduced primary HSC/Ps from WT or Gab2-/-mice with retrovirus expressing WT KIT or KITD814V and assessed proliferation. As seen in Figure 5B , deficiency of Gab2 resulted in significant repression (~75%) in ligand independent growth of cells bearing KITD814V similar to SHP2-/-cells ( Figure 1D ). These results suggest that SHP2 and Gab2 are essential and cooperate in KITD814V induced ligand independent growth.
Intracellular tyrosine residue at 719 in KIT receptor is sufficient for recruiting protein complex involving p85α, SHP2 and Gab2 to KITD814V
To assess whether binding of p85α to SHP2, Gab2 and KITD814V is sufficient to induce MPD, we generated a KIT mutant receptor, KITD814V-F7, in which seven tyrosine residues in KITD814V were converted to phenylalanine, and KITD814V-Y719, in which only tyrosine residue 719 (binding site for p85α) was added back to the KITD814V-F7 receptor. Supplemental Figure 9 shows a schematic of these mutant KITD814V receptors. Cells bearing WT KIT, KITD814V, KITD814V-Y719 and KITD814V-F7 were starved and subjected to immunoprecipitation assay with an anti-KIT antibody followed by western blotting with an antip85α antibody. The results show constitutive binding of p85α subunit to KITD814V and KITD814V-Y719, but not to WT KIT or KITD814V-F7 ( Figure 5C ). We further confirmed these results by reverse IP in which immunoprecipitation was done with an anti-p85α antibody followed by western blotting with an anti-KIT antibody (data not shown). In addition, constitutive binding of SHP2 and Gab2 to p85α was also observed in cells bearing KITD814V and KITD814V-Y719, but not in WT KIT or KITD814V-F7 bearing cells ( Figure 5C ). These results demonstrate that p85α recruits SHP2 and Gab2 to KITD814V at Y719, which might contribute to KITD814V induced MPD.
Tyrosine 719 associated p85α, SHP2 and Gab2 complex is sufficient for KITD814V induced ligand independent growth in vitro and MPD in vivo
To further determine the contribution of Y719 associated p85α, SHP2 and Gab2 complex in KITD814V induced ligand independent growth in vitro and MPD in vivo, we transduced primary HSC/Ps from Kit W-sh/W-sh mice, which lack endogenous KIT receptor, with retrovirus encoding KIT receptors and sorted to homogeneity. Similar expression of these receptors was confirmed by western blot analysis (Data not shown). As seen in Figure 6A , cells bearing WT KIT showed minimal thymidine incorporation in the absence of growth factors. In contrast, cells bearing oncogenic KITD814V showed constitutive growth in the absence of growth factors. However, conversion of all the seven intracellular tyrosine residues in KITD814V to phenylalanine (KITD814V-F7) resulted in complete loss of ligand independent growth ( Figure 6A ). Importantly, restoration of tyrosine residue at position 719 (KITD814V-Y719) was sufficient to induce ligand independent growth to a level similar to cells bearing the KITD814V receptor. These data suggest that the tyrosine residue at position 719, which is the binding site for class I A PI3Kinase regulatory subunit p85α, is sufficient to rescue ligand independent proliferation in vitro to KITD814V levels by recruiting a complex involving SHP2.
To assess whether the differences in ligand independent growth of cells bearing WT KIT, KITD814V, KITD814V-F7 and KITD814V-Y719 were due to differences in cell survival or cycling, myeloid cells bearing these KITD814V receptors were subjected to apoptosis and cell cycle analysis. As seen in Figure 6B , cells bearing KITD814V showed significantly increased survival compared to WT KIT bearing cells in the absence of growth factors. Loss of intracellular tyrosine residues in KITD814V (KITD814V-F7) abrogated ligand independent survival, and restoration of tyrosine residue at 719, KITD814V-Y719, was sufficient to completely maintain the survival of these cells to the levels seen in KITD814V bearing cells. These results demonstrate that Y719 is sufficient not only to restore the binding of SHP2 and Gab2 to p85α, but also sufficient to completely restore KITD814V induced ligand independent growth and survival. Figure 6C ). The median time of survival in these two groups was 59 days for KITD814V vs 55 days for KITD814V-Y719 ( Figure 6C ). These data suggest that the intracellular tyrosine residue at position 719, which recruits a complex of p85α, SHP2 and Gab2, is sufficient for KITD814V induced MPD. 
amount of protein lysates were subjected to western blotting with an anti-phospho-KIT, antiphospho-AKT or anti-phospho-ERK antibody. Constitutive activation of KIT, AKT, and ERK was observed in cells bearing KITD814V, but not WT KIT ( Figure 7A ). While treatment of these cells with II-B08 significantly reduced the phosphorylation of AKT and ERK in KITD814V bearing cells, no significant effect was observed on KIT phosphorylation in KITD814V bearing cells ( Figure   7A ). Similar results were observed in HMC1.2 cells derived from human mastocytosis patient (Supplemental Figure 10A) . Likewise, splenocytes derived from KITD814V bearing mice treated with II-B08 showed significantly reduced phosphorylation of ERK compared to splenocytes derived from KITD814V bearing mice treated with vehicle (DMSO) (Supplemental Figure 10B ).
These results suggest that SHP2 regulates ligand independent growth and survival of KITD814V bearing cells in part by regulating the activation of AKT and ERK, but not KIT tyrosine kinase activity.
SHP2 inhibitor, II-B08, enhances the efficacy of PI3Kinase inhibitor LY294002 in suppressing KITD814V induced ligand independent growth in vitro and MPD in vivo
To further determine whether a lipid kinase (PI3Kinase) and a tyrosine phosphatase (SHP2) cooperate in KITD814V induced ligand independent growth, we performed proliferation assay in the presence of PI3Kinase inhibitor LY294002 or SHP2 inhibitor II-B08 alone or in combination.
As seen in Figure 7B , low doses of LY294002 and II-B08 alone showed 50% reduction in ligand independent growth of cells bearing KITD814V. Importantly, treatment of these cells with a combination of LY294002 and II-B08 completely suppressed ligand independent growth ( Figure   7B ).
We next examined the in vivo consequence of KITD814V bearing mice with a combination of LY294002 and IIB08. For this, mice transplanted with cells bearing KITD814V were treated with either DMSO or II-B08 (50 mg/kg body weight) or PI3Kinase inhibitor LY294002 (10 mg/kg body weight) or combination of II-B08 and LY294002 (50 + 10 mg/kg body weight, respectively) at 24 hour intervals for 21 days. Mice were monitored for MPD development and survival. As seen in Figure 7C , mice treated with low doses of II-B08 or LY294002 survived significantly longer compared to DMSO treated group. Importantly, mice treated with a combination of II-B08 and LY294002 survived significantly longer compared to mice treated either with II-B08 or LY294002 alone ( Figure 7C ). Spleen size and weight of II-B08 or LY294002 or II-B08 and LY294002 treated mice was significantly reduced compared to DMSO treated group ( Figure 7D and 7E). Similar reduction in liver size and weight was observed in mice treated with II-B08 or LY294002 or II-B08 and LY294002 compared to DMSO ( Figure 7D and 7E KITD814V. Further, we observed constitutive binding of SHP2 to p85α and Gab2 in oncogenic KITD814V bearing cells, but not in WT bearing cells. Pharmacologic inhibition of SHP2 using II-B08 resulted in reduced tyrosine phosphorylation and reduced binding to p85α and Gab2.
Likewise, inhibition of SHP2 phosphorylation using II-B08 resulted in reduced activation of AKT in cells bearing oncogenic KITD814V. These results suggest that oncogenic KITD814V induced constitutive phosphorylation of SHP2 leading to enhanced recruitment to p85α and Gab2 complex results in prolonged activation of AKT and MPD.
Inhibition of SHP2 phosphatase has been speculated to be potentially relevant in diseases that bear activating mutations of SHP2, such as juvenile myelomonocytic leukemia, as well as in diseases in which SHP2 collaborates with other oncogenes to induce carcinogenesis, such as KIT in systemic mastocytosis and AML. Currently, no clinically relevant inhibitors of SHP2 phosphatase activity exist. The first published example of a SHP2 inhibitor was NSC-87877; however, this compound demonstrates no selectivity for SHP2 over the related protein tyrosine phosphatase, SHP1
39 . The inhibitor, phenylhydrazonopyrazolone sulfonate (PHPS1)
demonstrates improved specificity for SHP2 over SHP1; however, functional data utilizing this compound is limited to immortalized or transformed cell lines without clear disease indication 40 .
An additional study identified some SHP2-specific compounds; however, these compounds were only effective at inhibiting cellular proliferation at relatively high concentrations (100 μM) 41 .
The SHP2 phosphatase inhibitor, II-B08, demonstrates selectivity for SHP2 over the related phosphatases, SHP1 and PTP1B and, importantly, is able to block SHP2 activity within the cells, demonstrated by its highly efficacious effects in cell-based assays 18 . We also provide PK/PD data to suggest that II-B08 is well tolerated in vivo (See methods for pharmacokinetic studies).
The dose of II-B08 we employed in our studies, while results in 50% SHP2 inhibition in normal splenocytes ( Figure 3A) ; this degree of SHP2 inhibition does not impact normal hematopoiesis, Figure 2B) . Thus, the amount of SHP2 protein and its phosphorylation/activation status to a large extent determines functional outcomes in normal vs. For
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Blood. 1994;83(9):2619-2626. were starved for 8 hours in serum-and growth factor-free medium followed by incubation with or without II-B08 (20µM) for 1 hour. After incubation, equal amount of protein lysates were subjected to immunoprecipitation with anti-SHP2 or anti-p85α antibodies followed by western blot analysis using an anti-p85α, anti-SHP2 or anti-Gab2 antibodies. Similar results were observed in two independent experiments. (B) Primary BM derived cells expressing WT KIT or KITD814V from WT or Gab2-/-mice were starved and subjected to proliferation assay in the absence of growth factors by thymidine incorporation. Bars denote the mean thymidine incorporation (Mean ± SD) from one of three independent experiments performed in quadruplicate. *p < 0.01, WT-KITD814V vs. Gab2-/--KITD814V. (C) 32D cells bearing WT KIT, KITD814V, KITD814V-Y719 or KITD814V-F7 were starved of serum and growth factors for 8 hours and equal amount of protein lysates were subjected to immunoprecipitation with an anti-KIT antibody, anti-p85α antibody or anti-SHP2 antibody followed by western blot analysis using anti-KIT, anti-p85α, anti-SHP2 or anti-Gab2 antibodies as indicated. Similar results were observed in two to three independent experiments. Primary hematopoietic stem and progenitor cells (HSC/P) derived from W sh/sh mice, which lack endogenous expression of KIT receptor, were transduced with the indicated chimeric KIT receptors and sorted to homogeneity based on EGFP expression. Cells were starved in serumand growth factor-free media for 6 hours and subjected to proliferation assay in the absence of growth factors by thymidine incorporation. Bars denote the mean thymidine incorporation (CPM± SD) from one of the three independent experiments performed in quadruplicate. *p<0.05, WT KIT vs.KITD814V; **p<0.05, KITD814V vs. KITD814V-F7; ***p<0.05, KITD814V-F7 vs.
10.
For personal use only. on April 13, 2017. by guest www.bloodjournal.org starved for 6 hours followed by treatment with or without II-B08 (20µM) for 1 hour. After incubation, cells were lysed and equal amount of protein lysates were subjected to western blot analysis using an anti-phospho-KIT (Y719), total KIT, anti-phospho-AKT, total AKT, antiphospho-ERK or total ERK antibody as indicated. Similar results were observed in three independent experiments. (B) 32D cells bearing WT KIT or KITD814V were starved of serum and growth factors for 6 hours and subjected to proliferation assay in the presence or absence of PI-3K inhibitor (LY294002, 2µM) and SHP2 Inhibitor (II-B08, 5µM) alone or in combination.
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